- In Vivo Originals
- Featured Topics
Growth
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
-
Analysis
Alys Is An Asset Play Wanting Big Pharma Attention
Leaders of a new dermatology-focused biotech, which has launched with 14 development programs in its pipeline, explain the rationale behind the company creation and the ideal exit scenario.
-
Analysis
Genmab's Growth Strategy: Embracing A ‘Super Rational, Data-Driven' Mindset
By David WildThe “Genmab sauce” will be crucial as the Danish biotech loads up on late-stage assets, grows its capabilities and expands into immunology and inflammation.
-
Analysis
Medtech’s Leading Revenue Earners In 2023: Johnson & Johnson Tops $30bn
By Ashley YeoAbbott’s weaker rapid diagnostic sales see the erstwhile industry leader slip down the global 2023 medtech rankings, while Johnson & Johnson passes it on the way up on the back of strong external and internal growth.
-
Analysis
Advice From Investors On Early-Stage Financing
By David WildStartup financing may be hard to come by, but now is not the time to ask for less cash.
-
Analysis
The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest
By Joseph HaasEli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
-
Analysis
Private Equity And VC Fund Data: What Do The Numbers Show?
By Edwin ElmhirstIn Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.
-
Analysis
The Biopharma A List: Taking The Pulse Of Newco Creation
By Amanda MicklusOn the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
-
Analysis
Unpartnered Assets To Watch In 2024
By Edwin ElmhirstLicensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months.
-
Analysis
J.P. Morgan 2024: Financial Forecast Is Sunny For Firms Poised For Pharma Deals
By Mandy JacksonDrug developers weathered a tough 2023, but the year ended with new clarity about interest rates and big pharma M&A priorities, reducing the risk of financial storms in 2024, investors and advisors said.
-
Interviews
Rentschler’s New CEO On 2024 Expectations For CDMOs
By Lucie Ellis-TaittIn Vivo caught up with Benedikt von Braunmühl at the recent BIO-Europe conference in Munich, Germany, to discuss his first six weeks as CEO at Rentschler Biopharma and the biggest trends impacting contract development and manufacturing organizations (CDMO).
-
Analysis
Investment And Acquisition In Rare Diseases
By Jo ShorthouseIn Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.
-
Data
Scrip 100: By The Numbers
By Lucie Ellis-Taitt and Kosh NaranPfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.
-
Analysis
Industry Leaderboard Gains And Dips Were Still Marked By COVID-19
By Jessica Merrill and Edwin ElmhirstPfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.
-
Analysis
Macro Challenges Make Calls On Newly Resilient Medtechs
By Ashley YeoGlobal medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.
-
Analysis
Indian Leaders Climb Into Generics And Biosimilars Top 10
By David WallaceIn a year that has seen significant changes throughout the generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders. Meanwhile, companies lower down our ranking have enjoyed mixed fortunes, leading to a number of significant movements in this year’s Generics Bulletin Top 50.
-
Analysis
Europe’s Biotech Sector Still In Reasonable Shape
By Kevin GroganMoney may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.